FDA Warns of Risks in Compounded GLP-1 Drugs
Federal regulators warn consumers about safety risks and manufacturing contaminants in popular compounded weight-loss drugs. Despite shortages ending, telehealth firms and spas continue marketing knockoff GLP-1 medications.
Xurve View
Insights:
Xurve View
Federal drug regulators in the United States have stepped up enforcement against unapproved copycat weight-loss drugs following factory inspections and product recalls. The crackdown targets compounded versions of popular treatments amid rising safety concerns over overseas supply chains. The scrutiny highlights risks for consumers purchasing discounted alternatives outside the FDA-approved framework.
